Ebola vaccine R&D: Filling the knowledge gaps

Donata Medaglini,1* Ali M. Harandi,‡ Tom H. M. Ottenhoff,† Claire-Anne Siegrist,§ VSV-EBOVAC Consortium‡

With an emphasis on systems analyses, the VSV-EBOVAC project harnesses state-of-the-art technologies that illuminate mechanisms behind the observed immunogenicity and reactogenicity of the rVSV-ZEBOV vaccine and ensures that such information is shared among stakeholders.

In August 2014, after the Ebolavirus disease (EVD) outbreak hit six West African countries, the World Health Organization (WHO) created an African and European VSV-Ebola consortium (VEBCON) to initiate dose-escalation phase 1 clinical trials with a vesicular stomatitis virus (VSV)–Zaire Ebola virus virus candidate (rVSV-ZEBOV). When used at high doses in humans, the rVSV-ZEBOV Ebola vaccine elicited antibodies against the Ebola virus but also triggered an undesirable “reactogenic” response—including the development of viral oligoarthritis in multiple joints within the second week after vaccination—at discrepant frequencies across phase 1 clinical study sites. Lower doses reduced vaccine immunogenicity but did not prevent induction of arthritis. High doses of rVSV-ZEBOV proved to be efficacious in preventing Ebola virus disease within a few days after vaccination in a Guinea phase 3 clinical trial.

Now, the VSV-EBOVAC project on “Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV” aims to acquire in-depth knowledge of the innate and adaptive immune responses elicited by the rVSV-ZEBOV vaccine during the WHO-initiated phase 1 trials being conducted in Switzerland, Kenya, and Gabon. Here, we describe these efforts to fill the knowledge gaps in Ebola virus (EBOV) research and development (R&D).

UNMET NEED: EBOLA VACCINE

Named after the Ebola river in the Democratic Republic of Congo (DRC), EBOV first appeared in 1976 in simultaneous outbreaks in DRC and Sudan (1). The 2014 outbreak was first recognized in Guinea in March, with cases and deaths reported in six West African countries: Guinea, Liberia, Nigeria, Senegal, Mali, and Sierra Leone (www.cdc.gov) (2). The known-case rate has exceeded the largest prior EVD outbreak, which occurred in Uganda in 2000 to 2001, with more than 26,000 confirmed or probable cases and more than 10,000 deaths (3). The scale of this outbreak has led to extraordinary efforts from the WHO and other institutions in an attempt to treat victims and contain the spread of disease. Outbreaks manifest through person-to-person transmission, with infection resulting from direct contact with blood or other bodily fluids or organs of infected people, and indirect contact with environments contaminated by such fluids (1). The EVD incubation period is between 2 and 21 days (7 to 10 days on average) (4), followed by severe acute illness. Death can occur 6 to 16 days after the onset of symptoms, and mortality rate has been reported in some outbreaks to be as high as 90% (1, 4). Such high infectivity of blood and secretions puts health care workers at particularly high risk during outbreaks. No effective therapies or licensed vaccines exist for any member of the Filoviridae family of viruses, and an effective vaccine would maximize safety for those at greatest risk of disease during outbreaks.

A primary antibody response [immunoglobulin M (IgM)] can be detected in the blood of infected persons 2 to 9 days after infection, whereas appearance of virus-specific IgG antibodies occurs ~17 to 25 days after infection and coincide with the recovery phase. Both humoral and cellular immunity are detected in EVD survivors (5), but the mechanisms at play and their relative contributions to protection in humans remain unknown.

A vaccination strategy capable of rapidly eliciting protective immunity in most recipients through a single vaccination is needed, in particular, for populations in areas of the world where EVD is endemic and outbreaks occur sporadically. A promising Ebola vaccine candidate, a replication-competent version of VSV that expresses a surface glycoprotein of Zaire Ebola virus (rVSV-ZEBOV) (6, 7), was developed by the Public Health Agency of Canada in collaboration with several international partners (8) and licensed to NewLink Genetics and subsequently to Merck. The international consultation led by the WHO in September 2014 concluded that rVSV-ZEBOV was one of the only two candidates that had shown 100% protection in nonhuman primates and had clinical-grade material ready for testing in people (9–11). Researchers assessed the rVSV-ZEBOV vaccine’s potential for protection against newly emerging, phylogenetically related strains by immunizing macaques prior to challenge with Bundibugyo ebolavirus (BEBOV), a newly emerged Ebola virus species (12). A single vaccination with rVSV-ZEBOV provided significant cross-protection (75% survival), suggesting that monovalent rVSV-based vaccines can be useful against newly emerging species. Thus, VEBCON initiated dose-escalation phase 1 clinical trials in Germany, Kenya, Gabon, and Switzerland.

Preliminary results from the phase 1 trials indicated that a single high dose of rVSV-ZEBOV was immunogenic but also reactogenic (13, 14); high doses [3 × 10⁶ and 5 × 10⁷ plaque-forming units (PFU)] provoked mild to moderate, early-onset, transient symptoms such as fever, myalgia, chills, fatigue, and headaches in most subjects and were associated with viremia and hematomatological changes indicative of vaccine replication (14). EBOV–glycoprotein (GP)–specific IgG antibody responses were detected in all participants, with significantly higher titers of EBOV neutralizing antibodies at higher vaccine doses. However, oligoarthritis was reported in the second week after injection in 1 of the 51 Geneva trial participants, occasionally accompanied by vesicular dermatitis. The identification
of rVSV-ZEBOV in synovial fluid and skin vesicles confirmed viral dissemination and replication in peripheral tissues (15). Only two similar cases of arthritis were observed at other trial sites, which suggests an influence of the vaccine dose, host factors, or reporting and investigative approaches.

After a safety-driven study hold, the Geneva randomized clinical trial resumed at the markedly lower dose of $3 \times 10^5$ PFU and the Gabon trials at the same or lower doses—providing a singular opportunity to assess the relative influence of vaccine dose on vaccine safety and immunogenicity in the same patients. Reducing the vaccine dose stemmed acute reactogenicity, but did not prevent arthritis, dermatitis, or cutaneous vasculitis, and also decreased the magnitude of antibody responses (15). Nevertheless, no vaccine-associated severe adverse events were reported in any of the rVSV-ZEBOV phase 1 trials. Hence, the vaccine was selected for further phase 2/3 trials by WHO (Guinea), the U.S. Centers for Disease Control and Prevention (CDC) (Sierra Leone), and the U.S. National Institute of Health (NIH) (Liberia), along with the National Health Authorities in the host countries.

The Guinea trial was conducted by vaccinating all eligible and willing persons with an identified or potential contact with an EBOV-infected person, thus creating a potential protective “ring” to stop the virus from further spreading. The interim analysis included a total population of 7651 people, which was divided in two groups and vaccinated either immediately or after a 21-day delay. Recent results showed that at a high dose ($2 \times 10^5$ PFU), rVSV-ZEBOV was highly effective: No new cases of EVD were diagnosed in vaccinees from 6 days after vaccination (16).

These promising results call for in-depth studies to assess the induction and duration of immune memory responses and to identify the signatures of immunogenicity and reactogenicity—challenges that the VSV-EBOVAC project aims to address.

**GOALS:**

**KNOWLEDGE AND HARMONIZATION**

The VSV-EBOVAC project (www.vsv-ebovac.eu) is a transdisciplinary, multinational collaboration with a public health–oriented strategy that fills a translational gap in Ebola vaccine R&D and informs rational development of efficacious live vaccines with acceptable safety profiles for other life-threatening infections for which vaccines are not currently available. Supported by the European Commission Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU), the project brings together 12 leading international vaccine research institutes from six EU countries and the United States, as well as two African clinical sites (tables S1 and S2) and thus contributes to capacity building at the African sites by intimately involving scientists from these institutions and exchanging critical information. Several of the VSV-EBOVAC partners participate in the High Impact FP7 Project on Advanced Immunization Technologies (ADITEC; www.aditecproject.eu), a collaborative research program that involves 42 institution from 12 EU countries and the United States and aims to accelerate the development of new immunization technologies for next-generation human vaccines (17, 18).

VSV-EBOVAC’s key goal is to comprehensively characterize the molecular signatures of immune responses elicited by the rVSV-ZEBOV vaccine in humans. VSV-EBOVAC thus extends and enriches the dose-escalating phase 1 trials of the rVSV-ZEBOV vaccine conducted in Switzerland, Kenya, and Gabon by harnessing state-of-the-art technologies for systems analyses (transcriptomic and metabolomics profiling) of the human innate and adap-
tive immune responses to vaccination and by subsequently integrating these data with clinical findings (safety and immunogenicity) (Fig. 1). The project benefits from having access to the clinical samples of subjects who were vaccinated with different doses of the VSV-ZEOB vaccine and assessed at numerous early and subsequent time points (Table 1). The sharing of clinical samples collected at multiple time points from ~300 participants immunized with rVSV-ZEOB ensures sufficient power to decipher the influence of numerous demographic determinants, including gender and age, on vaccine safety and immune responses. Systems biology approaches have been used to pinpoint signatures of immunogenicity for only a few human vaccines (19). Integration of multiple layers of information derived from distinct “-omics” analyzed with clinical immunological measures might provide a better understanding of the complex mechanisms of protective immunity induced by vaccines than is possible with only conventional clinical and immunological readouts. For example, systems analyses might identify early gene signatures or other biomarkers predictive of magnitude, quality, and duration of vaccine-induced adaptive immune responses as well as surrogate markers of potential vaccine-induced adverse events. The VSV-EBOVAC project provides an opportunity to study molecular biomarkers of live-vaccine reactogenicity and immunogenicity. Results from this project could inform rational development of new live vaccines for other diseases with acceptable safety and immunogenicity profiles.

One of the intriguing features of VSV-ZEOB is that no EVD cases were reported in vaccinees later than 6 days after immunization. This implies that innate or very early adaptive immune responses support viral clearance and control. Given that plasma and blood samples were retrieved from the volunteers of these trials early after vaccination—that is, days 0, 3, 7, and 14—VSV-EBOVAC project offers a distinct opportunity to profile innate and adaptive immune responses induced by the vaccine at these very early time points when the protective response is in play. Such findings could then be bridged with parallel data to be generated from nonhuman primates after VSV-ZEOB vaccination and ZEOB challenge for cross validation.

The project represents a critical step forward through harmonization and in-depth integrated analyses of data generated through a variety of clinical, immunological, and molecular readouts—safety, immunogenicity, innate and adaptive immunity, immunological memory, transcriptomics, and metabolomics—and ensures that all information resulting from the ongoing first-in-humans clinical studies is exploited and shared. The results obtained from this project should enhance and accelerate the development of a safe and efficacious vaccine to counter Ebola infection in humans but also could provide a blueprint for the development of other future vaccines. The VSV-EBOVAC project will pursue interactions with other relevant Ebola vaccine efforts to ensure maximum coordination and harmonization, in order to enhance the worldwide capability to respond swiftly to future EVD outbreaks.

Table 1. Clinical trials studied in VSV-EBOVAC.

<table>
<thead>
<tr>
<th>Trial reference</th>
<th>Clinical site</th>
<th>Study start date</th>
<th>Vaccine* (PFU)</th>
<th>Number of participants</th>
<th>Visits (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT02287480</td>
<td>Geneva</td>
<td>November 2014</td>
<td>5 × 10^1†</td>
<td>16</td>
<td>(-90, -1) 0, 1, 3, 7, 14, 28, 84, 168</td>
</tr>
<tr>
<td></td>
<td>(Switzerland)</td>
<td></td>
<td>1 × 10^2</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3 × 10^1†</td>
<td>56</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Placebo</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>NCT02296983</td>
<td>Kilifi</td>
<td>December 2014</td>
<td>3 × 10^6</td>
<td>20</td>
<td>0, 1, 3, 7, 14, 28, 60, 90, 180</td>
</tr>
<tr>
<td></td>
<td>(Kenya)</td>
<td></td>
<td>1 × 10^5</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>PACTR201411000919191</td>
<td>Lambaréné</td>
<td>November 2014</td>
<td>2 × 10^2</td>
<td>20</td>
<td>0, 1, 2, 7, 14, 28, 56, 84, 180</td>
</tr>
<tr>
<td></td>
<td>(Gabon)</td>
<td></td>
<td>3 × 10^2</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3 × 10^1</td>
<td>20</td>
<td></td>
</tr>
</tbody>
</table>

*One single administration on Day 0 for each subject. †Arm interrupted on January 2015. ‡Started on January 2015.

SUPPLEMENTARY MATERIALS
http://stm.scienceemag.org/cgi/content/full/7/317/317ps24/
DC1 Table S1. Key VSV-EBOVAC data Table S2. List of VSV-EBOVAC consortium participants

REFERENCES AND NOTES


Funding: The VSV-EBOVAC project is supported by IM2J EU (www.im2j.eu), under grant agreement no. 115842, within the IMI Ebola+ program launched in response to the EVD outbreak in Western Africa in 2014. IM2 receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. The VSV-EBOVAC is coordinated by the Sclavo Vaccines Association (www.sclavo.org), a nonprofit organization devoted to support research and development of human vaccines. VEBCON trials: The Public Health Agency of Canada donated 800 vials of the rVSV-ZEBOV vaccine to WHO, which created VEBCON to initiate dose-escalation phase 1 clinical trials. These phase 1 trials were initiated in Germany (NCT02283099), Kenya (NCT02296983), Gabon (PACTR2014000089322), and Switzerland (a phase 1/2 randomized, controlled trial NCT02287480) and were supported financially through WHO by a grant from the Wellcome Trust Foundation, the Bill and Melinda Gates Foundation, and the German Center for Infection Research. Phase 2/3 Guinea trial: PACTR201503001057193. The VSV-EBOVAC Consortium: Selidji Todigbe Agnandji, Rafi Ahmed, Jenna Anderson, Floriane Auderset, Luisa Borjiani, Jessica Brosnahan, Annalisa Ciabattini, Olivier Engler, Marielle C. Hak, Gray Heppner, Alice Gerfin, Peter Gottfried Kremsner, Stephen Leib, Thomas Monath, Francis Ndungu, Patricia Ninuguna, Mark Page, Gianni Pozzi, Rino Rappuoli, Francesco Santoro, Marc Strasser. 10.1126/scitranslmed.aad3106

Ebola vaccine R&D: Filling the knowledge gaps
Donata Medaglini, Ali M. Harandi, Tom H. M. Ottenhoff, Claire-Anne Siegrist and VSV-EBOVAC Consortium (December 9, 2015)

Editor's Summary

The following resources related to this article are available online at http://stm.sciencemag.org. This information is current as of April 8, 2017.

Article Tools
Visit the online version of this article to access the personalization and article tools:
http://stm.sciencemag.org/content/7/317/317ps24

Supplemental Materials
"Supplementary Materials"
http://stm.sciencemag.org/content/suppl/2015/12/07/7.317.317ps24.DC1

Related Content
The editors suggest related resources on Science's sites:
http://stm.sciencemag.org/content/scitransmed/4/140/140sr2.full
http://stm.sciencemag.org/content/scitransmed/7/276/276fs9.full
http://stm.sciencemag.org/content/scitransmed/7/297/297ra114.full
http://stm.sciencemag.org/content/scitransmed/7/295/295ed8.full
http://stm.sciencemag.org/content/scitransmed/7/295/295ra109.full
http://science.sciencemag.org/content/sci/350/6277/1078.full
http://science.sciencemag.org/content/sci/351/6275/1293.full
http://science.sciencemag.org/content/sci/351/6277/1078.full
http://science.sciencemag.org/content/sci/351/6279/1339.full
http://science.sciencemag.org/content/sci/351/6279/1343.full
http://science.sciencemag.org/content/sci/353/6300/658.2.full
http://science.sciencemag.org/content/sci/353/6300/658.1.full
http://science.sciencemag.org/content/sci/353/6300/1073.full
http://science.sciencemag.org/content/sci/353/6305/1207.full
http://science.sciencemag.org/content/sci/354/6310/284.full
http://science.sciencemag.org/content/sci/354/6310/350.full
http://science.sciencemag.org/content/sci/355/6324/463.full

Permissions
Obtain information about reproducing this article:
http://www.sciencemag.org/about/permissions.dtl